Incorporation of biologic response variance modelling into the clinic: limiting risk of brachial plexopathy and other late effects of breast cancer proton beam therapy

ConclusionsInstitution of a BP biological dose constraint may reduce brachial plexopathy risk without compromising target coverage. MCBD plan evaluation provides valuable information to physicians which may assist in making clinical judgments regarding relative priority of target coverage vs. normal tissue sparing.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research